Literature DB >> 18778572

Update on pharmacotherapy guidelines for the treatment of neuropathic pain.

Douglas A Dobecki1, Sanford M Schocket, Mark S Wallace.   

Abstract

Neuropathic pain is a common problem in our society affecting nearly 1.5% of the US population. There currently are five medications approved by the US Food and Drug Administration (FDA) for the treatment of neuropathic pain, which include gabapentin, pregabalin, duloxetine, 5% lidocaine patch, and carbamazepine. Other agents with proven efficacy in multiple randomized, placebo-controlled trials include opioids, tricyclic antidepressants, venlafaxine, and tramadol. All of these agents, both FDA-approved and off-label, have been recommended as first-line treatments for neuropathic pain. This article discusses these agents in detail as they relate to the treatment of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18778572     DOI: 10.1007/s11916-006-0044-9

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  35 in total

1.  Venlafaxine in neuropathic pain following treatment of breast cancer.

Authors:  Tiina Tasmuth; Brita Härtel; Eija Kalso
Journal:  Eur J Pain       Date:  2002       Impact factor: 3.931

2.  The effect of opioids on phantom limb pain and cortical reorganization.

Authors:  E Huse; W Larbig; H Flor; N Birbaumer
Journal:  Pain       Date:  2001-02-01       Impact factor: 6.961

3.  Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.

Authors:  S H Sindrup; F W Bach; C Madsen; L F Gram; T S Jensen
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

Review 4.  Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.

Authors:  Søren H Sindrup; Troels S Jensen
Journal:  Pain       Date:  1999-12       Impact factor: 6.961

5.  Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study.

Authors:  B S Galer; M C Rowbotham; J Perander; E Friedman
Journal:  Pain       Date:  1999-04       Impact factor: 6.961

6.  Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Authors:  M Backonja; A Beydoun; K R Edwards; S L Schwartz; V Fonseca; M Hes; L LaMoreaux; E Garofalo
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

7.  Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.

Authors:  M Rowbotham; N Harden; B Stacey; P Bernstein; L Magnus-Miller
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

8.  Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.

Authors:  Julio Rosenstock; Michael Tuchman; Linda LaMoreaux; Uma Sharma
Journal:  Pain       Date:  2004-08       Impact factor: 6.961

9.  Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.

Authors:  C P Watson; N Babul
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

10.  Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.

Authors:  Y Harati; C Gooch; M Swenson; S Edelman; D Greene; P Raskin; P Donofrio; D Cornblath; R Sachdeo; C O Siu; M Kamin
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  7 in total

Review 1.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Ten common questions (and their answers) about off-label drug use.

Authors:  Christopher M Wittich; Christopher M Burkle; William L Lanier
Journal:  Mayo Clin Proc       Date:  2012-08-06       Impact factor: 7.616

Review 3.  An evidence-based algorithm for the treatment of neuropathic pain.

Authors:  Nanna B Finnerup; Marit Otto; Troels S Jensen; Søren H Sindrup
Journal:  MedGenMed       Date:  2007-05-15

4.  Gabapentin improves cold-pressor pain responses in methadone-maintained patients.

Authors:  Peggy Compton; Priscilla Kehoe; Karabi Sinha; Matt A Torrington; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2010-02-16       Impact factor: 4.492

5.  Enhancement of Antinociception by Co-administrations of Nefopam, Morphine, and Nimesulide in a Rat Model of Neuropathic Pain.

Authors:  Elham Saghaei; Taraneh Moini Zanjani; Masoumeh Sabetkasaei; Kobra Naseri
Journal:  Korean J Pain       Date:  2012-01-02

6.  Risk Factors Linked to Psychological Distress, Productivity Losses, and Sick Leave in Low-Back-Pain Employees: A Three-Year Longitudinal Cohort Study.

Authors:  Angelo Compare; Paolo Marchettini; Cristina Zarbo
Journal:  Pain Res Treat       Date:  2016-08-18

7.  SIRT3-Mediated CypD-K166 Deacetylation Alleviates Neuropathic Pain by Improving Mitochondrial Dysfunction and Inhibiting Oxidative Stress.

Authors:  Binbin Yan; Qiang Liu; Xiaobao Ding; Yuwen Lin; Xiaowei Jiao; Yuqing Wu; Huihui Miao; Chenghua Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-09-01       Impact factor: 7.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.